IDH2 and central nervous system cancer: While some studies highlight the potential of neuroimaging in predicting IDH mutation status,16 these approaches have yet to demonstrate diagnostic performance comparable to histopathology or molecular profiling17 due to numerous factors,18,19 including variability in imaging protocols, lack of standardization, and importantly gliomas’ microenvironmental heterogeneity.